177 results about "Target mrna" patented technology

The invention belongs to the technical field of genetic engineering, and particularly relates to a CsECT protein related to plant disease resistance, a recombinant vector and application of the CsECT protein. The invention provides a CsECT protein related to plant disease resistance, the CsECT protein is synthesized by gene CsECT coding, it is speculated that the gene CsECT is used as an m6A reader, metabolism of target mRNA of the gene CsECT is affected, the stability of disease resistance related target genes is improved, expression of disease resistance genes is promoted, and then the disease resistance of plants is improved. The result of the embodiment shows that after the CsECT gene is cloned, the CsECT transgenic citrus is constructed, the CsECT gene is excessively expressed by the transgenic citrus, the canker resistance of the citrus can be remarkably improved, and then the disease resistance of the citrus is improved. Therefore, the CsECT protein synthesized by the gene CsECT disclosed by the invention can be used for improving the disease resistance of plants.

The embodiment of the invention discloses an mRNA sequence generation method and device, a model training method and device and electronic equipment. The method comprises the steps that a target protein sequence, a target species text corresponding to the target protein sequence and target translation efficiency corresponding to the target protein sequence are obtained; determining a first target embedding corresponding to the target species text, determining a second target embedding corresponding to the target protein sequence, and determining a third target embedding corresponding to the target translation efficiency; splicing the first target embedding, the second target embedding and the third target embedding to obtain a fourth target embedding; a sequence generation model is called to map the fourth target embedding, a target mRNA sequence is generated, and the target mRNA sequence comprises a first coding region, a first untranslated region and a second untranslated region; according to the embodiment of the invention, the accurate and complete target mRNA sequence can be obtained, the application effect of the target mRNA sequence can be improved, and the method can be widely applied to scenes such as cloud technology, artificial intelligence and smart medical treatment.

The invention discloses a method for producing mRNA (messenger ribonucleic acid) template plasmids by fermenting escherichia coli. When the recombinant escherichia coli is fermented and cultured, a seed solution of the recombinant escherichia coli is inoculated into a basic culture medium to be fermented and cultured until the OD600 value of fermentation liquor is 18-22, then a fed-batch culture medium is continuously added at the feeding rate of 5-15 mL / L / h to be subjected to continuous fed-batch fermentation culture, the basic culture medium contains 0.05-0.2 mmoL / L of ferric salt compound and 0.05-0.2 mmoL / L of copper chloride dihydrate, and the basic culture medium contains 0.05-0.2 mmoL / L of ferric salt compound and 0.05-0.2 mmoL / L of copper chloride dihydrate. The basal culture medium contains 10-15 g / L of copper chloride dihydrate and 100-300 mg / L of p-hydroxybenzoic acid, the carbon source of the basal culture medium contains 0.1-0.3 mmoL / L of a ferric salt compound, 0.1-0.3 mmoL / L of copper chloride dihydrate and 100-300 mg / L of p-hydroxybenzoic acid, the carbon source of the fed-batch culture medium contains 360-480 g / L of glycerol, and the ferric salt compound is one or more of ferrous citrate, ferric ammonium citrate or ferrous sulfate heptahydrate. According to the method, the yield and superhelix content of the mRNA template plasmids are improved by optimizing the culture medium formula and culture conditions, and large-scale production of the high-quality target mRNA template plasmids is facilitated.

The present invention relates to the field of in vitro transcription, and particularly to a plasmid backbone capable of improving the stability of polyadenylate tails. The present invention provides an expression cassette, which sequentially includes: the rop gene, the replicon ori, and the resistance gene; the rop gene, the replicon ori, and the resistance gene are connected by a linking fragment. The present invention has established a low-copy pmRVacSL and a medium-copy pmRVacM plasmid vector system through artificial modification. Since pmRVacSL is a low-copy vector, the yield of plasmid DNA is relatively low. The pmRVacM plasmid backbone solves the problem of relatively low plasmid DNA yield of pmRVacSL. This vector system can not only maintain the stable replication of polyA tail sequences of more than 150 bp, but also quickly add genes of interest and polyadenylate (polyA) sequences, and efficiently and rapidly obtain the DNA template for in vitro transcription of the target mRNA.

The invention discloses an ovary-targeting mRNA liposome nanoparticle, a preparation method, a drug compound, a targeting delivery system and application, and relates to the technical field of liposome granules, the ovary-targeting mRNA liposome nanoparticle comprises the following components by mass: 20%-80% of SM-102, 1%-20% of PEG2000, 5%-40% of CHO-HP, 1%-20% of DSCP, and 0.01%-10% of targeting polypeptide, the target polypeptide comprises at least one of the following sequences: LVYKDPARPNTQK, RCGPCRLSSSDCGGPRTQPMACDLP, and CALCRRSTSDCGGPKDHPLT (recombinant human serum albumin), and the target polypeptide comprises at least one of the following sequences. The present invention provides a liposome nanoparticle for targeted ovary and uterus delivery of mRNA. The lipidosome nano-particles are specially researched, developed and designed for mRNA, have a good targeted delivery effect in mRNA in-vivo delivery, and can be applied to the field of targeted drug delivery of ovaries and uteruses. When in use, the kit can be directly prepared with a specific mRNA sequence for use, so that different application requirements can be flexibly met.

Embodiments of the present disclosure relate to a composition that comprises a recombinant plasmid (RP) with a sequence of nucleic acids. The sequence comprise a start region, an end region and an insert positioned between the start region and the end region. The insert encodes for a sequence of micro interfering ribonucleic acid (miRNA) that may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint protein.

The invention relates to an mRNA (messenger Ribonucleic Acid) vaccine targeting FomA and application of the mRNA vaccine in immunotherapy of esophageal squamous carcinoma in the technical field of tumor immunotherapy. The problems that in the prior art, a specific targeting vaccine for the fusobacterium nucleatum membrane protein FomA lacks, traditional antibiotics can only kill extracellular bacteria and cannot remove intracellular colonized fusobacterium nucleatum, and cellular immunity cannot be effectively activated to remove fusobacterium nucleatum colonized in tumor tissue; the immunotherapy drug resistance of esophageal squamous carcinoma caused by fusobacterium nucleatum infection is difficult to reverse. According to the technical scheme, an mRNA molecule with a fusobacterium nucleatum FomA extracellular domain tandem repeat sequence and a lipid nanoparticle delivery system are coded, an extramembrane segment tandem repeat immune enhancement technology is adopted for design, two extracellular ring sequences are repeated for 2-5 times and connected through a connector sequence, lipid nanoparticles are composed of optimized quaternary lipids, and the lipid nanoparticles are prepared from the quaternary lipids. And a PD-1 monoclonal antibody is combined to activate FomA specific CD8 + T cell immunoreaction, so that comprehensive removal of intracellular and extracellular bacteria and bacteria targeted immune remodeling are realized.

The invention discloses antisense oligonucleotides for reducing XDH gene expression in a targeted manner and application of the antisense oligonucleotides, and belongs to the technical field of biological medicines. The antisense oligonucleotide mediates the degradation of the target mRNA through an RNase H (RNase H) dependent cleavage mechanism, and the mRNA expression of the XDH gene is horizontally knocked down after transcription; the antisense oligonucleotide molecule has a specific nucleic acid sequence, is combined with chemical modification design, can specifically bind XDH mRNA molecules in a targeting manner, promote XDH mRNA degradation and inhibit XDH protein synthesis, so that the expression level of XDH in cells is reduced, uric acid synthesis is reduced, the purpose of reducing uric acid is finally achieved, and cell experiments and animal model tests show that the antisense oligonucleotide molecule has a good application prospect. The antisense oligonucleotide molecule disclosed by the invention has a good uric acid reducing effect, and is long in drug effect duration and high in drug safety.

Compositions are provided for transient transcriptional modulation of genes through delivery of RNA molecules encoding site-specific DNA binding molecules linked to transcriptional modulation domains, as well as methods for treating or preventing a disease or disorder, including a cancer, infectious disease, or immunological disease.

The present invention provides an oligonucleotide, wherein the oligonucleotide has at least 15 nucleotides sufficiently complementary to the target mRNA, wherein one or more sites of the oligonucleotide are conjugated to a lipophilic moiety.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.

Embodiments of the present disclosure relate to a composition that comprises a recombinant plasmid (RP) with a sequence of nucleic acids. The sequence comprise a start region, an end region and an insert positioned between the start region and the end region. The insert encodes for a sequence of micro interfering ribonucleic acid (miRNA) that may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint protein.

Embodiments of the present disclosure relate to a composition that comprises a recombinant plasmid (RP) with a sequence of nucleic acids. The sequence comprise a start region, an end region and an insert positioned between the start region and the end region. The insert encodes for a sequence of micro interfering ribonucleic acid (miRNA) that may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint protein.

The invention relates to a system for monitoring mRNA m6A methylation in hepatic stellate cells based on a hybridization chain reaction and a detection method, and belongs to the technical field of analysis and detection. In order to solve the problem of poor sensitivity and detection precision in the prior art, the invention provides a system for monitoring mRNA m6A methylation in hepatic stellate cells based on hybridization chain reaction and a detection method, the method comprises the following steps: contacting a target mRNA m6A methylation sample to be detected with a group of probes comprising a probe a and a probe b; the probe b is connected to an anti-rabbit IgG antibody to form a probe b attached with the anti-rabbit IgG antibody; combining with a rabbit monoclonal anti-m6A antibody; the rabbit monoclonal anti-m6A antibody can be combined with a target mRNA m6A methylated sample to be detected; a hairpin probe H1 monomer and a hairpin probe H2 monomer are subjected to a hybridization chain reaction to form a polymer, and imaging detection is carried out. The method has the advantages of high detection sensitivity, high detection selectivity and strong intuition.

The present application relates to the technical field of mRNA sequence evaluation, and discloses a kind of mRNA sequence safety evaluation method, device, electronic equipment and storage medium, the method comprises: obtaining target mRNA sequence;Extract the biophysical characteristics of target mRNA sequence;Biophysical characteristics include: primary structure characteristics, secondary structure characteristics and functional characteristics;Biophysical characteristics are input into the mRNA sequence safety evaluation model constructed in advance, and safety evaluation result is obtained.The primary structure characteristics, secondary structure characteristics and functional characteristics of mRNA sequence are considered as comprehensive factors and input into the mRNA sequence safety evaluation model, the internal correlation between sequence structure characteristics, spatial structure characteristics, translation function characteristics and safety can be accurately captured, and the accuracy and reliability of the model for mRNA sequence safety evaluation are effectively improved.

The invention relates to the technical field of poultry breeding, and particularly provides a novel application of miR-17-5p in chicken follicular development. Experiments prove that the miR-17-5p can inhibit autophagy and apoptosis of chicken follicular granular cells, so that granular cell proliferation can be promoted by promoting expression of the miR-17-5p in the chicken follicular granular cells, development of chicken ovary follicles is further promoted, and atresia is prevented. The invention also discovers that downstream target mRNA of miR-17-5p is MAP3K5, and researches find that MAP3K5 can promote autophagy and apoptosis of chicken follicular granular cells. The discovery provides a new thought for targeting particle cells to regulate dynamic balance between autophagy and apoptosis of the cells so as to improve the poultry breeding efficiency, and also expands the functional cognition of the JNK / BCL2 pathway in poultry research.

Some aspects of this disclosure provide compositions, methods, systems, and kits for controlling the activity and / or improving the specificity of RNA-programmable endonucleases, such as Cas9. For example, provided are guide RNAs (gRNAs) that are engineered to exist in an “on” or “off” state, which control the binding and hence cleavage activity of RNA-programmable endonucleases. Some aspects of this disclosure provide mRNA-sensing gRNAs that modulate the activity of RNA-programmable endonucleases based on the presence or absence of a target mRNA. Some aspects of this disclosure provide gRNAs that modulate the activity of an RNA-programmable endonuclease based on the presence or absence of an extended DNA (xDNA).

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a complement or a factor. In some embodiments of the present disclosure, the target biomolecule is a complement such as complement C1q, complement C1r, complement C1s, complement C3 or complement C5. In some embodiments of the present disclosure, the target biomolecule is a factor such as Factor B, Factor D or Factor 10.

Modified multi-segment antisense oligonucleotides and methods for reducing expression of target mRNA, DNA, and proteins are provided. Such methods, oligonucleotides, and compositions may be used to treat, prevent, or ameliorate a disease or disorder.

This invention relates to the field of biomedical detection technology, and discloses a bitetrahedral framework nucleic acid TDN cascade amplification system and its application, including TDN-1 and TDN-2. TDN-1 has a hairpin H1 containing a fluorescent reporter group attached to its surface, and TDN-2 has a hairpin H2 attached to its surface. The sequences of H1 and H2 are designed to undergo an alternating hybridization chain reaction triggered by target mRNA. This scheme relies on the synergistic effect of TDN structural anchoring and precise hairpin probe sequence design to overcome the technical defects of traditional free HCR hairpins in living cells, such as poor stability, low reaction efficiency, and non-specific triggering, achieving more efficient and specific intracellular signal amplification. Furthermore, it enables highly specific and sensitive in-situ imaging and dynamic tracking of low-abundance mRNAs such as c-Myc in single living cells, effectively solving the problems of insufficient detection sensitivity and false positives caused by the inability of traditional detection methods to effectively enrich targets and the low efficiency and high background of traditional HCR and other signal amplification technologies in intracellular applications.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.

The present disclosure relates to compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule, and the miRNA may cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is an opioid receptor. In some embodiments of the present disclosure, the target biomolecule is one or more of the mu opioid receptor, the delta opioid receptor, the kappa opioid receptor and the nociceptin opioid receptor.

The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule, such as CXCR5. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to expression of the target biomolecule.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.

Disclosed herein, are hammerhead ribozymes that bind to a target mRNA comprising a NUH ribozyme cleavage site that have enhanced turnover rates. Also described herein, are methods of administering hammerhead ribozymes that bind to a target mRNA comprising a NUH ribozyme cleavage site to treat eye diseases.

The invention provides a targeted mRNA delivery system of muscle tissues and / or muscle cells based on aptamer functionalized LNP (Apt-LNP), the delivery system can significantly improve mRNA transfection of the muscle tissues, and meanwhile, mRNA expression in main organs such as liver and spleen is greatly reduced. The expression intensity of muscle tissue in-situ mRNA is improved through modification of the aptamer, meanwhile, mRNA expression in main organs such as the liver and the spleen is greatly reduced, and side effects caused by off-target of mRNA infectious disease vaccines are expected to be avoided. The method is expected to be applied to the field of infectious disease mRNA vaccines The invention also provides a targeting mRNA delivery system of lymph node tissues and / or immune cells based on the aptamer functionalized LNP (Apt-LNP). Compared with an existing lymph node targeting system, the Apt-LNP modified by the aptamer not only can realize lymph node mRNA targeting, but also can further target immune cells, and is expected to be applied to the field of tumor mRNA vaccines to enhance the curative effect of tumor vaccines.

Embodiments of the present disclosure relate to a composition that comprises a recombinant plasmid (RP) with a sequence of nucleic acids. The sequence comprise a start region, an end region and an insert positioned between the start region and the end region. The insert encodes for a sequence of micro interfering ribonucleic acid (miRNA) that may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint protein.

A single-stranded oligonucleotide having a length of 16-30 nucleotides. The composition of the single-stranded oligonucleotide enables the single-stranded oligonucleotide to inhibit the expression of target mRNA by means of an RNAi mechanism. Each nucleotide in the single-stranded oligonucleotide is independently a modified or unmodified nucleotide, wherein at least one nucleotide in the single-stranded oligonucleotide is a nucleotide X; at least one nucleotide is a fluoro-modified nucleotide; and, in the 5' to 3' direction, the 13th nucleotide of the single-stranded oligonucleotide is a substituted alkoxy-modified nucleotide, the 14th nucleotide of the single-stranded oligonucleotide is a nucleotide X, and each of the 15th nucleotide and all subsequent nucleotides of the single-stranded oligonucleotide is independently a modified nucleotide. A double-stranded oligonucleotide comprising the single-stranded oligonucleotide as an antisense strand, an oligonucleotide conjugate and a pharmaceutical composition.

The embodiment of the invention discloses an mRNA translation efficiency prediction method and device, a model training method and device and electronic equipment, and the method comprises the steps that a target mRNA sequence and a target species text are obtained, and the target mRNA sequence comprises a first coding region, a first untranslated region and a second untranslated region; determining first target inserts corresponding to the first coding area, the first non-translated area and the second non-translated area, and splicing each first target insert with the corresponding first prompt insert to obtain a corresponding second target insert; determining a third target embedding corresponding to the target species text, splicing the third target embedding and the plurality of second target embedding to obtain a fourth target embedding, and calling a translation efficiency prediction model to generate target translation efficiency; according to the embodiment of the invention, the method can improve the accuracy of predicting the translation efficiency of mRNA, and can be widely applied to the scenes of cloud technology, artificial intelligence, smart medical treatment and the like.